Background Background Although there is a
Although there is a consensus that clozapine is more effective consensus that clozapine is more effective than conventional antipsychotic drugs for than conventional antipsychotic drugs for treatment-resistant schizophrenia, there treatment-resistant schizophrenia, there is great heterogeneity among results of is great heterogeneity among results of relevanttrials. relevanttrials.
Aims Aims To re-evaluate the evidence
To re-evaluate the evidence comparing clozapine with conventional comparing clozapine with conventional antipsychotics and to investigate sources of antipsychotics and to investigate sources of heterogeneity. heterogeneity.
Method Method Individual studies were
Individual studies were inspected with assessment of clinical inspected with assessment of clinical relevance of results.Meta-regression relevance of results.Meta-regression analysis was performed to investigate analysis was performed to investigate sources of heterogeneity. sources of heterogeneity.
Results
Results Ten trials were examined.
Ten trials were examined. Recentlarge-scale studies have notfound a Recentlarge-scale studies have notfound a substantial advantage for clozapine, substantial advantage for clozapine, especially in terms of a clinically relevant especially in terms of a clinically relevant effect.Meta-regression showed that effect.Meta-regression showed that shorter study duration, financial support shorter study duration, financial support from a drug company and higher baseline from a drug company and higher baseline symptom score consistently predicted symptom score consistently predicted greater advantage of clozapine. greater advantage of clozapine.
Conclusions Conclusions It may be inappropriate
It may be inappropriate to combine studies in meta-analysis, given to combine studies in meta-analysis, given the degree of heterogeneity between the degree of heterogeneity between their findings.The benefits of clozapine their findings.The benefits of clozapine compared with conventional treatment compared with conventional treatment may not be substantial. may not be substantial.
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Since the publication of the landmark study Since the publication of the landmark study by Kane by Kane et al et al (1988) , clozapine has been (1988) , clozapine has been regarded as an effective treatment for regarded as an effective treatment for people with treatment-resistant schizopeople with treatment-resistant schizophrenia, defined as failing to respond to phrenia, defined as failing to respond to standard antipsychotic drug treatment. A standard antipsychotic drug treatment. A Cochrane review of comparative randomCochrane review of comparative randomised trials concluded that clozapine is more ised trials concluded that clozapine is more effective than conventional antipsychotics effective than conventional antipsychotics for all patients with schizophrenia and that for all patients with schizophrenia and that the comparative advantage of clozapine is the comparative advantage of clozapine is greater in patients whose condition is greater in patients whose condition is classified as treatment-resistant (Wahlbeck classified as treatment-resistant (Wahlbeck et al et al, 1999 (Wahlbeck et al et al, , 2000 (Wahlbeck et al et al, , 1999 (Wahlbeck et al et al, , 2000a . However, despite this ). However, despite this consensus, subsequent large-scale trials of consensus, subsequent large-scale trials of clozapine in treatment-resistant schizoclozapine in treatment-resistant schizophrenia have failed to replicate the phrenia have failed to replicate the dramatic effects achieved by Kane dramatic effects achieved by Kane et al et al, , finding at best only small differences finding at best only small differences (Essock (Essock et al et al, 1996; Rosenheck , 1996; Rosenheck et al et al, , 1997) . Another recent Cochrane review 1997). Another recent Cochrane review found no difference between the efficacy found no difference between the efficacy of other 'atypical' agents and clozapine in of other 'atypical' agents and clozapine in patients with treatment-resistant schizopatients with treatment-resistant schizophrenia (Tuunainen phrenia (Tuunainen et al et al, 2002) . In the , 2002). In the light of these findings, the trials comparing light of these findings, the trials comparing clozapine and conventional antipsychotics clozapine and conventional antipsychotics for treatment-resistant conditions were for treatment-resistant conditions were re-examined. In particular, the clinical re-examined. In particular, the clinical relevance of the results of later studies relevance of the results of later studies was examined and possible causes of was examined and possible causes of heterogeneity between studies were heterogeneity between studies were investigated. investigated. RANDOMISED TRIAL were used. This RANDOMISED TRIAL were used. This located one additional trial that had located one additional trial that had been been conducted on patients with treatmentconducted on patients with treatmentresistant disease. An additional trial was resistant disease. An additional trial was identified from the Cochrane review that identified from the Cochrane review that had not been included in the treatmenthad not been included in the treatmentresistant analysis, but was found to involve resistant analysis, but was found to involve participants with treatmentparticipants with treatment-resistant resistant schizophrenia. In total nine studies were schizophrenia. In total nine studies were identified (Table 1) . identified (Table 1) .
METHOD METHOD
Individual study results were tabulated Individual study results were tabulated and examined. The difference in symptom and examined. The difference in symptom scores between the clozapine group and scores between the clozapine group and the comparison group at the end of treatthe comparison group at the end of treatment as a percentage of the post-treatment ment as a percentage of the post-treatment score in the control group was calculated. score in the control group was calculated. This was done in order to compare results This was done in order to compare results with the 20% difference that is commonly with the 20% difference that is commonly said to represent clinically significant imsaid to represent clinically significant improvement in individuals in terms of sympprovement in individuals in terms of symptom ratings in treatment-resistant cases tom ratings in treatment-resistant cases (Rosenheck (Rosenheck et al et al, 1997; Wahlbeck , 1997; Wahlbeck et al et al, , 1999) . 1999).
Meta-analysis was conducted to examMeta-analysis was conducted to examine heterogeneity between studies, which ine heterogeneity between studies, which is assessed by testing the weighted variation is assessed by testing the weighted variation of individual study results about the mean of individual study results about the mean effect. The outcomes of individual trials effect. The outcomes of individual trials were converted to standardised mean were converted to standardised mean differences (SMDs) to allow the results of differences (SMDs) to allow the results of studies using different outcome measures studies using different outcome measures to be combined. The SMD is usually calto be combined. The SMD is usually calculated as the difference between the mean culated as the difference between the mean of the experimental group and the mean of of the experimental group and the mean of the control group divided by the combined the control group divided by the combined standard deviation (Hedges & Olkin, standard deviation (Hedges & Olkin, 1985) . The level of symptoms at the end 1985). The level of symptoms at the end of the study or change in symptoms over of the study or change in symptoms over the course of the study was defined as the the course of the study was defined as the main outcome of interest, since this is the main outcome of interest, since this is the principal objective of clozapine therapy in principal objective of clozapine therapy in treatment resistance. All studies used either treatment resistance. All studies used either the Brief Psychiatric Rating Scale (BPRS; the Brief Psychiatric Rating Scale (BPRS; Overall & Gorham, 1962) , 1987) to rate symptoms. Intention-to-treat data were used if Intention-to-treat data were used if possible. In one study (Rosenheck possible. In one study (Rosenheck et al et al, , 1997 ) standard deviations were not avail-1997) standard deviations were not available for the intention-to-treat data and so able for the intention-to-treat data and so the standard deviations obtained from the the standard deviations obtained from the analysis of treatment completers were used analysis of treatment completers were used instead. instead.
In the study by Essock In the study by Essock et al et al (1996 Essock et al et al ( ) it (1996 it was difficult to decide which data to use was difficult to decide which data to use as the basis for calculating SMD, since this as the basis for calculating SMD, since this was a naturalistic study and a large prowas a naturalistic study and a large proportion of people in the control group were portion of people in the control group were prescribed clozapine at some point during prescribed clozapine at some point during the study. Intention-to-treat data were the study. Intention-to-treat data were available for change in BPRS score at the available for change in BPRS score at the end of the study from a later publication end of the study from a later publication by the same authors, who noted that the by the same authors, who noted that the results were similar when the analysis results were similar when the analysis was performed with crossovers excluded was performed with crossovers excluded (Essock (Essock et al et al, 2000) . The intention-to-treat , 2000). The intention-to-treat data were therefore used as the primary data were therefore used as the primary basis for calculating SMDs, but sensitivity basis for calculating SMDs, but sensitivity analysis was conducted using post-treatment analysis was conducted using post-treatment scores with crossovers excluded. In this case scores with crossovers excluded. In this case standard deviation was calculated from the standard deviation was calculated from the t t-value provided (Essock -value provided (Essock et al et al, 1996) and , 1996) and the number of patients in each group the number of patients in each group was provided on request by the authors was provided on request by the authors (N. (N. Covell, personal communication, Covell, personal communication, 2002) . Sensitivity 2002). Sensitivity analysis was also conanalysis was also conducted using nonducted using non-intention-to-treat data intention-to-treat data from the study by Kane from the study by Kane et al et al (2001 Kane et al et al ( ), for (2001 , for reasons explained below. reasons explained below. Meta-regression analysis was then Meta-regression analysis was then conducted to investigate possible sources conducted to investigate possible sources of heterogeneity. This consists of a of heterogeneity. This consists of a weighted regression analysis using the weighted regression analysis using the individual study SMDs as the data points. individual study SMDs as the data points. The following trial characteristics were The following trial characteristics were investigated to see whether they predicted investigated to see whether they predicted outcome in terms of the SMD: outcome in terms of the SMD: (e) (e) whether financial support from the whether financial support from the pharmaceutical industry was received; pharmaceutical industry was received;
(f) (f) whether a pre-trial high-dose treatment whether a pre-trial high-dose treatment period was employed; period was employed;
(g) (g) the ratio of dosage of clozapine to the ratio of dosage of clozapine to comparator drug (in chlorpromazine comparator drug (in chlorpromazine equivalents). equivalents).
These factors were considered These factors were considered a priori a priori to be potential predictors of outcome. to be potential predictors of outcome. Duration was considered to be a source of Duration was considered to be a source of heterogeneity in the Cochrane review heterogeneity in the Cochrane review (Wahlbeck (Wahlbeck et al et al, 2000 (Wahlbeck et al et al, , 2000a . There has also ). There has also been some suggestion that initial severity been some suggestion that initial severity (Umbricht (Umbricht et al , 2000a a) might ) might predict outcome. Size of study was exampredict outcome. Size of study was examined as a proxy for study quality and ined as a proxy for study quality and because it may indicate publication bias because it may indicate publication bias (Sterne (Sterne et al et al, 2001) . Year of publication , 2001). Year of publication was examined to assess whether there was was examined to assess whether there was an effect of the initial enthusiasm for a an effect of the initial enthusiasm for a novel treatment. The effect of a pre-trial novel treatment. The effect of a pre-trial treatment period was examined because of treatment period was examined because of the possibility that this could introduce the possibility that this could introduce selection bias by excluding participants selection bias by excluding participants who respond to a new trial of a standard who respond to a new trial of a standard antipsychotic. Dose ratio was examined antipsychotic. Dose ratio was examined because of suggestions that the use of because of suggestions that the use of overly high dosages of comparator drugs overly high dosages of comparator drugs have contributed to clozapine's apparent have contributed to clozapine's apparent superiority. superiority.
A univariate analysis was conducted A univariate analysis was conducted to explore the associations between outto explore the associations between outcome and the individual hypothesised come and the individual hypothesised explanatory variables. The reduction of explanatory variables. The reduction of the tau-squared value (that is, the the tau-squared value (that is, the residual variance between study results) residual variance between study results) was noted for each analysis. The analysis was noted for each analysis. The analysis was repeated using the data-set with nonwas repeated using the data-set with nonintention-to-treat data for the studies by intention-to-treat data for the studies by Essock Essock et al et al (1996) and Kane (1996) and Kane et al et al (2001) . Multivariate analysis was con-(2001). Multivariate analysis was considered but it was decided that there were sidered but it was decided that there were too few trials for it to produce reliable too few trials for it to produce reliable results. results.
All meta-analysis was conducted using All meta-analysis was conducted using the STATA version 7.0 statistical package the STATA version 7.0 statistical package (Stata, 2001) . (Stata, 2001) .
RESULTS RESULTS
Overview of individual studies Overview of individual studies Table 1 shows the characteristics of the Table 1 shows the characteristics of the nine trials of clozapine nine trials of clozapine v.
v. conventional conventional 1 6 2 1 6 2 (Table 1) . between 38 and 84 (Table 1) . Table 2 shows the results of individual Table 2 shows the results of individual studies according to the outcome measures studies according to the outcome measures used in each. It is clear that there is great used in each. It is clear that there is great variation between study results. The study variation between study results. The study by Kane by Kane et al et al (1988) is the only sizeable (1988) is the only sizeable trial to have found a substantial and trial to have found a substantial and unequivocal difference between clozapine unequivocal difference between clozapine and standard neuroleptics. The largest trial and standard neuroleptics. The largest trial conducted found only small differences in conducted found only small differences in symptom scores and improvement rates in symptom scores and improvement rates in the intention-to-treat analysis, although the intention-to-treat analysis, although the former are reported to be statistically the former are reported to be statistically significant because of the large sample size significant because of the large sample size (Rosenheck (Rosenheck et al et al, 1997) . The large natural-, 1997). The large naturalistic study by Essock istic study by Essock et al et al (1996) is difficult (1996) is difficult to interpret because 66% of patients in the to interpret because 66% of patients in the control group were given clozapine at some control group were given clozapine at some time during the course of the trial. There time during the course of the trial. There were no differences on symptom scores at were no differences on symptom scores at the end of the trial, both in intention-tothe end of the trial, both in intention-totreat analysis and analysis excluding crosstreat analysis and analysis excluding crossovers. Survival analysis of improvement overs. Survival analysis of improvement rates in the two groups showed almost rates in the two groups showed almost 1 6 3 1 6 3 identical survival curves, according to the identical survival curves, according to the authors. Slight differences favouring clozaauthors. Slight differences favouring clozapine at the end of the study were based on pine at the end of the study were based on small numbers and were not felt to represmall numbers and were not felt to represent real differences (N. Covell, personal sent real differences (N. Covell, personal communication, 2002 Covell, personal communication, ). communication, 2002 .
Only two studies reported data on rates Only two studies reported data on rates of re-hospitalisation or discharge. Essock of re-hospitalisation or discharge. Essock et et al al (1996) reported that there was no differ- (1996) reported that there was no difference in discharge rates between patients ence in discharge rates between patients assigned to clozapine and those assigned assigned to clozapine and those assigned to 'usual care', but patients in the clozapine to 'usual care', but patients in the clozapine group who were discharged were less likely group who were discharged were less likely to be readmitted. Rosenheck to be readmitted. Rosenheck et al et al (1997 Rosenheck et al et al ( ) (1997 found no difference in the proportion of found no difference in the proportion of patients who were readmitted during the patients who were readmitted during the study but found that overall the group of study but found that overall the group of patients assigned to clozapine spent 24 patients assigned to clozapine spent 24 fewer days in psychiatric in-patient beds. fewer days in psychiatric in-patient beds. Neither of the out-patient trials presented Neither of the out-patient trials presented data on admission rates. data on admission rates. Table 2 also shows the difference in Table 2 also shows the difference in improvement ratings on the main outcome improvement ratings on the main outcome measure expressed as a percentage of the measure expressed as a percentage of the post-treatment score for the control group. post-treatment score for the control group. This difference was greatest in the two This difference was greatest in the two earliest trials, but falls far short of the earliest trials, but falls far short of the 20% clinically relevant difference in the 20% clinically relevant difference in the more recent trials. Exceptions are the small more recent trials. Exceptions are the small trial in children (Kumra trial in children (Kumra et al et al, 1996) , the , 1996), the study conducted in Taiwan (Hong study conducted in Taiwan (Hong et al et al, , 1997) and the latest study of out-patients 1997) and the latest study of out-patients (Kane (Kane et al et al, 2001 ). The last is the only , 2001). The last is the only long-term study to find that clozapine was long-term study to find that clozapine was substantially superior to a typical antisubstantially superior to a typical antipsychotic. It is worth noting therefore that psychotic. It is worth noting therefore that 50% of patients in the haloperidol group 50% of patients in the haloperidol group were withdrawn because of 'lack of were withdrawn because of 'lack of efficacy'. It is difficult to understand this efficacy'. It is difficult to understand this finding in a group of patients who were finding in a group of patients who were considered stable enough to live in the considered stable enough to live in the community. The fact that they had to be community. The fact that they had to be withdrawn from the trial suggests that their withdrawn from the trial suggests that their condition had deteriorated more than condition had deteriorated more than would be expected in the normal course would be expected in the normal course of events. Information on how these of events. Information on how these patients fared subsequently is necessary to patients fared subsequently is necessary to address this possibility. It is also unusual address this possibility. It is also unusual that the rate of withdrawal because of the that the rate of withdrawal because of the lack of efficacy was chosen as the main lack of efficacy was chosen as the main measure of outcome. Considering only measure of outcome. Considering only patients who remained in the trial, final patients who remained in the trial, final total BPRS scores were similar for groups total BPRS scores were similar for groups allocated to haloperidol ( allocated to haloperidol (n n¼11, mean 11, mean 40.2, s.d. 40.2, s.d.¼12.2) and to clozapine ( 12.2) and to clozapine (n n¼23, 23, mean 37.5, s.d. mean 37.5, s.d.¼9.0). Rates of withdrawal 9.0). Rates of withdrawal were also very variable across trials, were also very variable across trials, ranging from 9.5% to 43% in the clozapine ranging from 9.5% to 43% in the clozapine groups and from 8 to 72% in the control groups and from 8 to 72% in the control groups. groups.
Meta-analysis
Meta-analysis Figure 1 shows that heterogeneity between Figure 1 shows that heterogeneity between study results was substantial and the statisstudy results was substantial and the statistical test for heterogeneity was highly tical test for heterogeneity was highly significant ( significant (Q Q¼38.2, d.f.
38.2, d.f.¼8, 8, P P5 50.001). 0.001). Overall meta-analysis using intention-toOverall meta-analysis using intention-totreat data and a fixed effects model treat data and a fixed effects model produced an overall effect of 0.38 standard produced an overall effect of 0.38 standard deviations (95% CI 0.27-0.50) in favour of deviations (95% CI 0.27-0.50) in favour of clozapine over the standard antipsychotic. clozapine over the standard antipsychotic. A random effects model yielded a similar A random effects model yielded a similar result of 0.44 standard deviations (95% result of 0.44 standard deviations (95% CI 0.15-0.73). The between-study variance CI 0.15-0.73). The between-study variance was 0.14. Even when trials were grouped was 0.14. Even when trials were grouped according to their duration, heterogeneity according to their duration, heterogeneity was still substantial. For the three longwas still substantial. For the three longterm trials the heterogeneity statistic was term trials the heterogeneity statistic was 12.9 ( 12.9 (P P¼0.002) and for the six short-term 0.002) and for the six short-term studies it was 11.1 ( studies it was 11.1 (P P¼0.05). 0.05). Table 3 shows the results of univariate Table 3 shows the results of univariate meta-regression analysis. Using the meta-regression analysis. Using the intention-to-treat data-set, it was found intention-to-treat data-set, it was found that duration, initial BPRS score and finanthat duration, initial BPRS score and financial support from the pharmaceutical induscial support from the pharmaceutical industry predicted outcome. Studies that found try predicted outcome. Studies that found larger differences in favour of clozapine larger differences in favour of clozapine were of shorter duration and the particiwere of shorter duration and the participants had higher initial BPRS scores. Trials pants had higher initial BPRS scores. Trials where there was information that some fiwhere there was information that some financial support had been provided by the nancial support had been provided by the pharmaceutical company manufacturing pharmaceutical company manufacturing clozapine also showed a greater benefit of clozapine also showed a greater benefit of clozapine compared with the conventional clozapine compared with the conventional neuroleptic. Study duration had the neuroleptic. Study duration had the 1 6 4 1 6 4
Fig. 1 Fig. 1 Forest plot using intention-to-treat data and fixed effect estimate for studies listed inTable 1.
Forest plot using intention-to-treat data and fixed effect estimate for studies listed inTable 1. 0.54 (0.14), 0.54 (0.14), P P5 50.001 0.001 5 50.001 0.001
Year of publication Year of publication 0.06 (0.02), 0.06 (0.02), P P5 50.001 0.001 5 50.001 0.001 BPRS, Brief Psychiatric Rating Scale; CPZeq, chlorpromazine equivalent. BPRS, Brief Psychiatric Rating Scale; CPZeq, chlorpromazine equivalent. 1. Variables were continuous except for sponsorship, which was coded as 1 for some financial support from a drug 1. Variables were continuous except for sponsorship, which was coded as 1 for some financial support from a drug company and 0 for no company support. company and 0 for no company support. 2. Tau-squared is the between-studies variance calculated using restricted maximum-likelihood method. 2. Tau-squared is the between-studies variance calculated using restricted maximum-likelihood method. 3. All trials except one (Klieser & Schonell, 1990 ) gave details of funding sources. 3. All trials except one (Klieser & Scho« nell, 1990 ) gave details of funding sources.
strongest effect on outcome and reduced strongest effect on outcome and reduced the between-study variance by the greatest the between-study variance by the greatest amount. amount. Using the data-set with non-intentionUsing the data-set with non-intentionto-treat data for Essock to-treat data for Essock et al et al (1996) and (1996) and Kane Kane et al et al (2001) showed that the same (2001) showed that the same variables predicted outcome, but also variables predicted outcome, but also showed a significant and strong effect for showed a significant and strong effect for year of publication with between-study varyear of publication with between-study variance reduced to zero. Source of financial iance reduced to zero. Source of financial support had a stronger effect in this analysis support had a stronger effect in this analysis and also reduced between-study variance to and also reduced between-study variance to zero. zero.
DISCUSSION DISCUSSION

Methodological limitations Methodological limitations
There are several caveats to these findings. There are several caveats to these findings. All reviews -including meta-analysesAll reviews -including meta-analysesinvolve subjective judgements, for example involve subjective judgements, for example in the selection of outcome measures and in the selection of outcome measures and data with which to conduct the analysis. data with which to conduct the analysis. Sensitivity analyses have been performed Sensitivity analyses have been performed where the author felt that there were where the author felt that there were grounds for debate about which set of stagrounds for debate about which set of statistics to use in any given study and, in partistics to use in any given study and, in particular, where arguments could be made ticular, where arguments could be made not to include crossovers or withdrawals. not to include crossovers or withdrawals. In addition, results of individual studies In addition, results of individual studies are summarised qualitatively as well as are summarised qualitatively as well as quantitatively. quantitatively.
The effect of treatment on symptom The effect of treatment on symptom levels was chosen for the purposes of the levels was chosen for the purposes of the meta-analysis and exploration of heterogemeta-analysis and exploration of heterogeneity. This was felt to be the best reflection neity. This was felt to be the best reflection of the objectives of clozapine treatment, of the objectives of clozapine treatment, and as such was present in all trials. Other and as such was present in all trials. Other main published outcomes are summarised, main published outcomes are summarised, but were not used in the meta-analysis. but were not used in the meta-analysis. Continuous data have been used, since Continuous data have been used, since these were available for all studies, whereas these were available for all studies, whereas categorical data were not. Moreover, categorical data were not. Moreover, categorical data may be more subject to categorical data may be more subject to bias, if the basis of categorisation has not bias, if the basis of categorisation has not been specified been specified a priori a priori. . Meta-regression analysis has severe Meta-regression analysis has severe limitations in a small set of nine trials. limitations in a small set of nine trials. The small number of studies limits its The small number of studies limits its power, but despite this some consistently power, but despite this some consistently significant effects were found. The results significant effects were found. The results for year of publication were only apparent for year of publication were only apparent within the data with withdrawals excluded, within the data with withdrawals excluded, which demonstrates the sensitivity of the which demonstrates the sensitivity of the analysis to decisions about which data to analysis to decisions about which data to use. It is also important to note that metause. It is also important to note that metaregression is an uncontrolled analysis, regression is an uncontrolled analysis, which lacks the protection of randomiswhich lacks the protection of randomisation. It must therefore be viewed cauation. It must therefore be viewed cautiously as an exploratory procedure. In tiously as an exploratory procedure. In addition, since multiple regression was not addition, since multiple regression was not performed, the possibility of correlation or performed, the possibility of correlation or confounding between explanatory variables confounding between explanatory variables could not be explored. could not be explored.
Overall findings Overall findings
Despite clozapine's reputation, there is Despite clozapine's reputation, there is substantial heterogeneity among trials substantial heterogeneity among trials comparing clozapine with conventional comparing clozapine with conventional antipsychotics for treatment-resistant antipsychotics for treatment-resistant schizophrenia. Most recent trials have not schizophrenia. Most recent trials have not replicated the dramatic superiority shown replicated the dramatic superiority shown by clozapine in early trials. In particular, by clozapine in early trials. In particular, they fail to demonstrate that the differences they fail to demonstrate that the differences between clozapine and conventional antibetween clozapine and conventional antipsychotics are clinically relevant in terms psychotics are clinically relevant in terms of the degree of difference in reduction of of the degree of difference in reduction of BPRS or other symptom scores. It is inter-BPRS or other symptom scores. It is interesting to note that so far no differences esting to note that so far no differences have been found between the effects of have been found between the effects of clozapine and other atypical antipsychotics clozapine and other atypical antipsychotics in patients with treatment-resistant in patients with treatment-resistant schizophrenia (Tuunainen schizophrenia (Tuunainen et al et al, 2002 (Tuunainen et al et al, ). , 2002 , 2000a a) might also have overestimated ) might also have overestimated the effects of clozapine by using nonthe effects of clozapine by using nonintention-to-treat data in the largest study, intention-to-treat data in the largest study, by Rosenheck by Rosenheck et al et al (1997) , and by exclud-(1997), and by excluding the large study by Essock ing the large study by Essock et al et al (1996 Essock et al et al ( ) (1996 from the analysis of effects on mental state. from the analysis of effects on mental state. The reasons for excluding the findings of The reasons for excluding the findings of Essock Essock et al et al (1996) from this analysis were (1996) from this analysis were not given but it may be because not all not given but it may be because not all the data required were available in the the data required were available in the published paper. Other results from the published paper. Other results from the study were included in other analyses. study were included in other analyses.
Sources of heterogeneity Sources of heterogeneity
In the Cochrane review including all clozaIn the Cochrane review including all clozapine trials, no association was found pine trials, no association was found between various measures of trial quality between various measures of trial quality and outcome, but whether a study had and outcome, but whether a study had received commercial sponsorship did received commercial sponsorship did predict some outcomes (Wahlbeck predict some outcomes (Wahlbeck et al et al, , 1999 (Wahlbeck et al et al, , , 2000 (Wahlbeck et al et al, , 1999 (Wahlbeck et al et al, , , 2000b . In the current analysis it ). In the current analysis it appeared that shorter duration of trial, appeared that shorter duration of trial, higher levels of baseline symptoms, higher levels of baseline symptoms, commercial support and possibly earlier commercial support and possibly earlier year of publication predicted greater superiyear of publication predicted greater superiority of clozapine over conventional antiority of clozapine over conventional antipsychotics.
The influence of the psychotics.
The influence of the pharmaceutical industry has probably been pharmaceutical industry has probably been understated in some studies, since understated in some studies, since published reports declared only whether published reports declared only whether the study had received direct funding from the study had received direct funding from a pharmaceutical company. Financial a pharmaceutical company. Financial interests of individual authors were not interests of individual authors were not declared. The duration of the study also declared. The duration of the study also emerged as a strong predictor of outcome, emerged as a strong predictor of outcome, suggesting that initial beneficial effects suggesting that initial beneficial effects may not be maintained over the long term. may not be maintained over the long term. Only one small long-term study suggested Only one small long-term study suggested that clozapine might have substantial that clozapine might have substantial benefits (Kane benefits (Kane et al et al, 2001) . However, the , 2001). However, the high withdrawal rate from the haloperidol high withdrawal rate from the haloperidol group in this trial requires explanation group in this trial requires explanation and may have some bearing on the results and may have some bearing on the results obtained. obtained.
All trials in the current analysis used All trials in the current analysis used relatively high daily doses of conventional relatively high daily doses of conventional antipsychotics, including the most recent antipsychotics, including the most recent study (Kane study (Kane et al et al, 2001 ). There was prob-, 2001). There was probably not enough variation in comparative ably not enough variation in comparative dosage levels therefore to examine the dosage levels therefore to examine the impact on outcome adequately. This may impact on outcome adequately. This may explain why the results do not confirm explain why the results do not confirm those of Geddes those of Geddes et al et al (2000) , who found (2000), who found that the advantages of atypical antithat the advantages of atypical antipsychotics were apparent only when doses psychotics were apparent only when doses greater than 12 mg of haloperidol or greater than 12 mg of haloperidol or equivalent were used. equivalent were used.
Initial severity and effects Initial severity and effects of clozapine of clozapine
Although all patients in the trials examined Although all patients in the trials examined were classified as having treatment-resistant were classified as having treatment-resistant disease, there was considerable variation disease, there was considerable variation between trials in average severity of between trials in average severity of baseline symptoms. The current analybaseline symptoms. The current analysis suggests that among patients with sis suggests that among patients with treatment-resistant disease, the benefits of treatment-resistant disease, the benefits of clozapine may be most marked in those clozapine may be most marked in those with higher levels of initial symptoms. with higher levels of initial symptoms. Other data on the relationship between Other data on the relationship between response to clozapine and severity of illness response to clozapine and severity of illness are inconsistent. In the large study of US are inconsistent. In the large study of US veterans included here, 'high hospital users' veterans included here, 'high hospital users' showed a smaller advantage for clozapine showed a smaller advantage for clozapine over haloperidol in terms of symptom reover haloperidol in terms of symptom reduction than 'low hospital users' (Rosenduction than 'low hospital users' (Rosenheck heck et al et al, 1999) . In addition, differences , 1999). In addition, differences between clozapine and haloperidol were between clozapine and haloperidol were not significant in the 'high user' group. In not significant in the 'high user' group. In the later out-patient study, patients who the later out-patient study, patients who were functioning at a lower level at trial enwere functioning at a lower level at trial entry as measured by Clinical Global Imprestry as measured by Clinical Global Impression scores (Guy, 1976) were less likely to sion scores (Guy, 1976) were less likely to show an enhanced response rate to clozashow an enhanced response rate to clozapine compared with haloperidol (Umbricht pine compared with haloperidol (Umbricht et al et al, 2002) . However, curiously, when this , 2002) . However, curiously, when this was controlled for, higher baseline rates of was controlled for, higher baseline rates of symptoms as measured by the BPRS presymptoms as measured by the BPRS predicted better relative response rates to clodicted better relative response rates to clozapine. The relationship between severity zapine. The relationship between severity and efficacy found in this analysis may and efficacy found in this analysis may therefore be an ecological effect that may therefore be an ecological effect that may not necessarily translate to the individual not necessarily translate to the individual level. It is also not possible to know from level. It is also not possible to know from the current analysis whether the greater the current analysis whether the greater benefit of clozapine in patients with higher benefit of clozapine in patients with higher baseline symptom levels would be mainbaseline symptom levels would be maintained in the long term, since all long-term tained in the long term, since all long-term studies were conducted with patients who studies were conducted with patients who had lower levels of baseline symptoms. had lower levels of baseline symptoms. There is substantial variation between results of different studies, which appears to be accounted for by study duration and funding and level of initial symptoms. to be accounted for by study duration and funding and level of initial symptoms.
& & Clozapine's greatest advantage relative to standard medication may be seen in Clozapine's greatest advantage relative to standard medication may be seen in patients with very high levels of initial symptoms. patients with very high levels of initial symptoms.
LIMITATIONS LIMITATIONS
& & Statistical analyses were based on results relating to symptom reduction only.
Statistical analyses were based on results relating to symptom reduction only.
& & Meta-regression analysis was sensitive to use of different data from some trials. Meta-regression analysis was sensitive to use of different data from some trials.
& & Only one study compared clozapine with a moderate rather than a large dose of Only one study compared clozapine with a moderate rather than a large dose of conventional drugs, meaning that the effects of dose could not be adequately conventional drugs, meaning that the effects of dose could not be adequately explored. explored.
